TĂNG BẬC VÀ GIẢM BẬC TRONG ĐIỀU TRỊ MÀY ĐAY TỰ PHÁT MẠN TÍNH
##plugins.themes.vojs.article.main##
Abstract
Chronic spontaneous urticaria (CSU) is defined by the spontaneous occurrence of itchy wheals, angioedema, or both, without any apparent reason, for > 6 weeks. The disease can appear at any time and in any body location. The disease is difficult to treat and poses a great challenge for both patients and doctors. The goal of treating chronic spontaneous urticaria is to “treat the disease until it is gone”, as effectively and safely as possible. Stepping up or stepping down treatment must follow the Assess – Act – Adjust – Re-assess principle. There are no biological markers to assess the level of disease activity, the level of disease control as well as evaluate the spontaneous remission of the disease. This assessment is based on clinical symptoms and scores self-assessed by the patient. To date, most treatment guidelines for chronic urticaria only provide instructions on how to step up treatment, but no instructions mention how to step down and when to step down or stop treatment. It is recommended that according to the experience of experts, step-down treatment should be gradually reduced and then stopped completely instead of stopping suddenly.
##plugins.themes.vojs.article.details##
Keywords
Mày đay tự phát mạn tính, điều trị ARV, giảm bậc, Chronic spontaneous urticaria, treatment, stepping down
References
[2] Pavel Kolkhir et al, "Urticaria," Nature Reviews, vol. 8:61, 2022.
[3] Maurer M, et al, "The burden of chronic spontaneous urticaria is substantial: Real-world evidence from ASSURE-CSU," Allergy, vol. 72(12), pp. 2005-16, 2017.
[4] Dorothea Terhorst Molawi et al, "Stepping Down Treatment in Chronic Spontaneous Urticaria: What We Know and What We Don’t Know," American Journal of Clinical Dermatology, vol. 24, pp. 397-404, 2023.
[5] Saini SS, Kaplan AP, "Chronic Spontaneous Urticaria: The Devil’s Itch," J Allergy Clin Immunol Pract, vol. 6(4), p. 1097–106, 2018.
[6] Giménez-Arnau AM, Salman A, "Targeted Therapy for Chronıc Spontaneous Urtıcarıa: Ratıonale and Recent Progress," Drugs, vol. 80(16), p. 1617–34, 2020.
[7] Hải, N. D. ., Hưng, N. T. ., & Diệp, L. N., "Nghiên cứu đặc điểm lâm sàng bệnh nhân mày đay mạn tính tại bệnh viện Da liễu Thành phố Hồ Chí Minh," Tạp Chí Y học Cộng đồng, vol. 64(5), 2023.
[8] Torsten Zuberbier et al, "The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria," Allergy, vol. 77, pp. 734-766, 2022.
[9] Doña, I. et al, "Progress in understanding hypersensitivity reactions to nonsteroidal anti-inflammatory drugs," Allergy, vol. 75, pp. 561-575, 2020.
[10] Lê Thị Kiều Nhi, Trần Quốc Khánh, Nguyễn Sơn Tùng, Phạm Lê Duy, "Đặc điểm cân lâm sàng của bệnh nhân mày đay mạn tính tại bệnh viện Đại học Y dược Thành phố Hồ Chí Minh," Y Học TP. Hồ Chí Minh, vol. 26(1), 2022.
[11] "Experience-based advice on stepping up and stepping down the therapeutic management of chronic spontaneous urticaria: Where is the guidance?," Allergy, pp. 1626 - 1630, 2022.
[12] Baiardini I, et al, "A new tool to evaluate the impact of chronic urticaria on quality of life: chronic urticaria quality of life questionnaire (CU-QoL)," Allergy, vol. 60(8), pp. 1073-8, 2005.
[13] Weller K, et al, "Development and construct validation of the angioedema quality of life questionnaire," Allergy, vol. 67(10), pp. 1289-98, 2012.